Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection [16S rRNA]

ABSTRACT: Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection [16S rRNA]

PROVIDER: PRJNA784544 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17065816_1.fastq.gz	Fastqsanger.gz
	SRR17065816_2.fastq.gz	Fastqsanger.gz
	SRR17065817_1.fastq.gz	Fastqsanger.gz
	SRR17065817_2.fastq.gz	Fastqsanger.gz
	SRR17065818_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection

Project description:Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection

| PRJNA784538 | ENA

Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection [16S rRNA]

Project description:The gut microbiome is intricately coupled with immune regulation and metabolism, but its role in Coronavirus Disease 2019 (COVID-19) is not fully understood. Severe and fatal COVID-19 is characterized by poor anti-viral immunity and hypercoagulation, particularly in males. Via 16S sequencing of antibiotic-treated mice, we found that Clostridia species protect mammalian hosts from SARS-CoV-2 intranasal infection, both locally and systemically, via production of short-chain fatty acids (SCFAs). SCFAs reduced viral burdens in the airways and intestines by downregulating the SARS-CoV-2 entry receptor, angiotensin-converting enzyme 2 (ACE2), and enhancing adaptive immunity in male animals. In order to identify other mechanisms by which SCFAs influence the outcome of SARS-CoV-2 infection, we performed RNA-seq on lungs from male GF mice given control or SCFA water for two weeks. We identified a novel role for the gut microbiome in regulating systemic coagulation response by limiting megakaryocyte proliferation and platelet turnover via the Sh2b3-Mpl axis. Taken together, our findings have unraveled novel functions of SCFAs and fiber-fermenting gut bacteria that might be leveraged as pan-coronavirus therapeutics to dampen viral entry and hypercoagulation and promote adaptive anti-viral immunity.

2022-08-02 | GSE189791 | GEO

Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection [RNA-Seq]

Project description:Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection [RNA-Seq]

| PRJNA784543 | ENA

Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-08-02 | GSE189794 | GEO

Gut microbiota-derived metabolites confer protection against SARS-CoV-2 infection [RNA-Seq]

Project description:The gut microbiome is intricately coupled with immune regulation and metabolism, but its role in Coronavirus Disease 2019 (COVID-19) is not fully understood. Severe and fatal COVID-19 is characterized by poor anti-viral immunity and hypercoagulation, particularly in males. Here we define multiple pathways by which the gut microbiome protects mammalian hosts from SARS-CoV-2 intranasal infection, both locally and systemically, via production of short-chain fatty acids (SCFAs). SCFAs reduced viral burdens in the airways and intestines by downregulating the SARS-CoV-2 entry receptor, angiotensin-converting enzyme 2 (ACE2), and enhancing adaptive immunity in male animals. In order to identify other mechanisms by which SCFAs influence the outcome of SARS-CoV-2 infection, we performed RNA-seq on lungs from male GF mice given control or SCFA water for two weeks. We identified a novel role for the gut microbiome in regulating systemic coagulation response by limiting megakaryocyte proliferation and platelet turnover via the Sh2b3-Mpl axis. Taken together, our findings have unraveled novel functions of SCFAs and fiber-fermenting gut bacteria that might be leveraged as pan-coronavirus therapeutics to dampen viral entry and hypercoagulation and promote adaptive anti-viral immunity.

2022-08-02 | GSE189792 | GEO

Inhalation of ACE2-expressing lung spheroid cell exosomes provides prophylactic protection against SARS-CoV-2

Project description:We demonstrated that lung spheroid cell derived exosomes (LSC-Exo) carry the parental cell’s ACE2 that are able to target lung, intercept SARS-CoV-2 entry, confer protection against SARS-CoV-2 infection. This LSC-Exo prophylaxis paradigm would not be limited by viral evolution, showing great potential for emerged SARS-CoV-2 variants, including those that are yet to emerge.

2024-01-13 | PXD047542 | Pride

Long-lived central memory gamma delta T cells confer protection against murine cytomegalovirus reinfection

Project description:Long-lived central memory gamma delta T cells confer protection against murine cytomegalovirus reinfection

| PRJNA1121371 | ENA

ILC1 confer early host protection at initial sites of viral infection

Project description:ILC1 confer early host protection at initial sites of viral infection

| PRJNA407437 | ENA

Glucocorticoids target the CXCL9/10-CXCR3 axis and confer protection against immune-mediated kidney injury

Project description:Glucocorticoids target the CXCL9/10-CXCR3 axis and confer protection against immune-mediated kidney injury

| PRJNA899146 | ENA

Mucosal Boosting Enhances Vaccine Protection Against SARS-CoV-2 in Rhesus Macaques

Project description:A major limitation of current SARS-CoV-2 vaccines is that they provide minimal protection against acquisition of infection with current Omicron subvariants, although they still provide protection against severe disease. It has been hypothesized that enhanced mucosal immunity will be required to block infection and onward transmission. Intranasal administration of current vaccines has proven inconsistent, suggesting that alternative immunization strategies may be required. Here we show that intratracheal boosting with a bivalent Ad26 based SARS-CoV-2 vaccine results in substantial induction of mucosal humoral and cellular immunity and near complete protection against SARS-CoV-2 BQ.1.1 challenge.

2024-02-14 | GSE245040 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data